CSL to apply for flu vaccine registration
data on the vaccine against the H5N1 strain of avian influenza will enable CSL,
the Melbourne-based company, to seek approval from the Therapeutic Goods
CSL Ltd., the world's
second-largest maker of blood plasma products, said it will apply to Australia's drugs regulator to
register a vaccine designed to protect people against a pandemic sparked by bird
flu. CSL is among more than 20 drug makers trying to speed production of
vaccines to help governments prepare for a possible pandemic that health
officials said could kill millions of people. CSL is the only supplier of
influenza vaccines based in the southern hemisphere.
"The ultimate goal of our research program is to develop a pandemic
vaccine which uses the lowest dose of antigen, which can offer cross-protection
against similar but non-identical bird flu strains, and which lasts as long as
possible,'' Andrew Cuthbertson, CSL's chief scientific officer said. Shares of
CSL rose as much as 1.3%, on the Australian Stock Exchange. They have gained 8% since January
1st. The Australian government contributed A$7.2 million ($5.5 million) to the
costs of CSL's pandemic vaccine development program including the vaccine
"The vaccine was found to be safe and well-tolerated in the study
population of adults aged 18 to 65,'' the company said. "Results of a subsequent
study undertaken in infants, young children and the elderly are expected to be
available later this year.''
begins major flu testing
For the latest
poultry news, subscribe here.
To comment, login here
Or register to be able to comment.